RxDoctor Payments Data

Kim Landzberg, MD

Ophthalmology · Bronx, NYNPI 1942218151

Payments from drug & device makers

$1,531in general payments, 2019–2025

Across 77 payments — averaging $19.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$323
  • Alcon$255
  • AbbVie$220
  • Aerie Pharmaceuticals, Inc.$168
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$165
  • Novartis$154
  • plus $246 from 6 others

What the payments were for

  • Food & beverage$1,531100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,531 in reported general payments places this provider in the 50th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$282,790
Medicare patients
619
Services billed
2,715

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine57$76,840
LumiganBimatoprost150$67,693
ProlensaBromfenac Sodium94$33,865
CombiganBrimonidine Tartrate/Timolol56$24,041
Timolol Maleate264$22,399
RocklatanNetarsudil Mesylat/Latanoprost41$19,234
RhopressaNetarsudil Mesylate37$17,391
Alphagan PBrimonidine Tartrate34$15,443
SimbrinzaBrinzolamide/Brimonidine Tart46$13,254
Travoprost61$11,320
Difluprednate111$10,506
VyzultaLatanoprostene Bunod12$9,505
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol45$8,467
Latanoprost472$5,112
Travatan ZTravoprost15$4,977

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$220$184,017297 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$168$36,62678 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate$165$36,581114 claims
AlconSimbrinza$255$13,25446 claims
Bausch & Lomb Americas Inc.Vyzulta$150$9,50512 claims
NovartisTravatan Z$154$4,97715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →